DelMar Pharmaceuticals Named to the “Ready to Rocket” List for the Second Year in a Row

VANCOUVER, BRITISH COLUMBIA--(Feb. 28, 2012) DelMar Pharma today announced Rocket Builders has included DelMar Pharma in its annual “Ready to Rocket” list for the second year in a row.

The annual “Ready to Rocket” list is the only predictive list of its kind in North America, requiring many months of sector and company analysis in three different technology sectors: Information and Communications; Cleantech and Life Science. The list seeks to provide accurate predictions of private companies that will likely experience significant growth, venture capital investment or acquisition. Since 2003, the Ready to Rocket list has consistently predicted the revenue growth leaders and the companies most likely to attract investment.

According to Thealzel Lee, Senior Partner at Rocket Builders, “B.C. has a strong tradition of creating successful companies in Life Science sectors like biotechnology and medical devices. DelMar Pharma has advanced from an emerging company to clinical-stage player in a short period time. They are truly a company to watch.”

Jeffrey Bacha, DelMar Pharma’s President & CEO said, “We are very pleased to again be included in this distinguished list. The “promotion” from an emerging to a the full “Ready to Rocket” list is recognition for our past accomplishments and our potential for future success both in terms of value creation and benefit to patients suffering from serious cancers.”

About DelMar Pharma

Del Mar Pharmaceuticals was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. DelMar’s lead asset, VAL‐083, benefits from extensive clinical research sponsored by the US National Cancer Institute, and is currently approved as a cancer chemotherapeutic overseas. Efficacy has been demonstrated in a range of tumor types, including glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. In 2011, DelMar initiated a Phase I/II clinical trial in refractory GBM with VAL‐083.

For further information, please visit www.delmarpharma.com or contact Jeffrey A. Bacha, President & CEO (604) 629‐5989

Released February 28, 2012